Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
- To determine the effect of Avastin on tumor blood flow as determined by functional
computed tomography (CT) in patients with low or intermediate grade neuroendocrine
carcinoma.
- To determine the effect of RAD001 on tumor blood flow as determined by functional CT in
patients with low or intermediate grade neuroendocrine carcinoma.
- To determine the effect of adding the second agent (Avastin or RAD001) to the first
agent (RAD001 or Avastin) on tumor blood flow as determined by functional CT
Secondary Objectives:
- To determine the clinical activity (objective response rate and progression free
survival duration) of Avastin and RAD001 in patients with low or intermediate grade
neuroendocrine carcinoma.
- To determine the biochemical response rate of Avastin and RAD001 in patients with low or
intermediate grade neuroendocrine carcinoma.
- To determine the safety and tolerability of Avastin and RAD001 in patients with low or
intermediate grade neuroendocrine carcinoma.